FindTrial
Sign In

Reliability of the *on-site test* for gamma-hydroxybutyric acid (GHB) and the clinical relevance of this test: On-site DrugCheck® GHB Single Test * Express Diagnostics®

Reliability of the *on-site test* for gamma-hydroxybutyric acid (GHB) and the clinical relevance of this test: On-site DrugCheck® GHB Single Test * Express Diagnostics® - Reliability and clinical relevance of an on-site GHB test.

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42350
Enrollment
910
Registered
2015-12-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis intake GHB identification intake GHB.

Interventions

None listed

Sponsors

Onze Lieve Vrouwe Gasthuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with age 18-45 year with reduced consciousness GCS* 8 Patients with age 18-45 year without reduced consciousness who declare to have taken in GHB.

Exclusion criteria

Exclusion criteria: Age 45 year

Design outcomes

Primary

MeasureTime frame
Determining the sensitivity and specificity of the on-site GHB test by comparing the results with the HPLC-MS/MS results.—

Secondary

MeasureTime frame
1. Cinical relevance is determined based on a questionnaire filled in by the doctor, containing questions about the influence of the results of the test regarding the treatment. 2. Alcohol promillages are measured in blood to rule out possible interference of alcohol on the test. 3. Urine samples with a fals-postive on-site testresults are subjected to a urine toxscreen to determine interference with other drugs of abuse. 4. The sensitivity and specificity of an immunoassaytechnique for the measurement of GHB-concentrations in urine will be investigated.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)